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ABSTRACT
Objective: To compare expected outcomes and costs of
care in patients with chronic schizophrenia or schizoaf-
fective disorders who are treated with risperidone versus
olanzapine.
Methods: A Markov model was developed to examine
outcomes and costs of care in patients with chronic
schizophrenia or schizoaffective disorders receiving risp-
eridone or olanzapine. The time frame of interest was
1 year. The model focused particular attention on the
likelihood of therapy switching and discontinuation as a
result of treatment-emergent side effects, as the efﬁcacy
of these two agents is similar. Measures of interest
included the incidence of relapse and selected side effects
including extrapyramidal symptoms (EPS), prolactin-
related disorders and diabetes, expected change in body
weight, and the percentage of patients remaining on ini-
tial therapy at the end of 1 year. Costs of antipsychotic
therapy and psychiatric and nonpsychiatric services also
were examined.
Results: At 1 year, the rate of EPS was estimated to be
slightly higher for risperidone, as was the incidence of
symptomatic prolactin-related disorders. The expected
incidence of diabetes mellitus, while low, was slightly
higher for olanzapine. Approximately 25% and 4% of
olanzapine and risperidone patients, respectively, were
projected to experience an increase in body weight ≥7%.
The estimated percentage of patients remaining on initial
therapy at the end of 1 year was higher for risperidone
than olanzapine (76.9% vs. 45.6%, respectively).
Expected mean total costs of care per month of therapy
were $2163 for risperidone and $2316 for olanzapine.
Results from sensitivity analyses suggest that the proba-
bility of therapy discontinuation following weight gain
>5 kg would have to be lower than 0.1 for the number of
patients remaining on therapy at the end of 1 year to be
the same for risperidone and olanzapine.
Conclusions: Compared with risperidone, treatment with
olanzapine may result in greater increases in body weight,
higher rates of therapy discontinuation, and higher costs
of medical-care services.
Keywords: atypical antipsychotics, costs, modeling, out-
comes, side effects.
Introduction
While conventional antipsychotics are known to be
effective in controlling symptoms in patients with
schizophrenia, side effects—especially extrapyrami-
dal symptoms (EPS)—have limited their utility in
clinical practice [1,2]. The atypical antipsychotics,
such as risperidone and olanzapine, have substan-
tially better side-effect proﬁles and tolerability than
conventional agents [2–4]. Nonetheless, while EPS
occurs less frequently with these newer medications,
other side effects remain a concern. Patients who
receive risperidone, for example, sometimes expe-
rience increased serum prolactin levels [5–7],
although the incidence of symptomatic disease
appears to be low [8–12]. Weight gain, on the other
hand, appears to be more of a problem with olan-
zapine [13–34].
A meta-analysis that examined over 80 studies
that included data on weight change in patients
receiving antipsychotics concluded that olanzapine
was associated with increases in body weight
between 3.9 and 4.5 kg at 10 weeks of treatment on
standard doses [15]; corresponding estimates for
risperidone were 1.7 and 2.5 kg. Long-term studies
have reported average increases of 4 kg to 11 kg
over 6 months for olanzapine [17,18,34]. The
percentage of olanzapine-treated patients with
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increases in body weight ≥7%—which the US Food
and Drug Administration has deﬁned to be “signif-
icant” [26]—has been estimated to exceed 26%
[6,16,29]. The Consensus Development Conference
on Antipsychotic Drugs and Obesity and Diabetes
[35] recently recommended that any patient who
experiences a >5% increase in body weight follow-
ing initiation of an atypical antipsychotic agent be
considered for therapy switching. Drug-induced
weight gain is of potential concern, as overweight
and obesity have been linked to various acute and
chronic disease conditions, including hypertension,
diabetes, coronary heart disease (CHD), and stroke
[36], and approximately 6% of total US health-care
spending is attributable to obesity-related diseases
[37].
Hyperglycemia, de novo diabetes, and diabetic
ketoacidosis also have been reported in patients
receiving olanzapine between 5 weeks and 17
months following therapy initiation; cases among
patients receiving risperidone have been less fre-
quent [38–50]; the annual incidence of diabetes has
been estimated to range from 0.1% to 6.7% for ris-
peridone, and from 0.7% to 14.3% for olanzapine
[51–58]. The US Food and Drug Administration
recently asked all manufacturers of atypical antip-
sychotics to include a warning in their package labe-
ling concerning the risks of hyperglycemia and
diabetes mellitus [59,60].
Side effects are an important cause of noncom-
pliance, therapy switching, and treatment discontin-
uation, all of which can increase costs of care and
decrease the effectiveness of pharmacotherapy in
clinical practice. While the efﬁcacy of risperidone
and olanzapine in controlling symptoms of schizo-
phrenia is well established, the impact of their side
effects on outcomes and costs of care has not yet
been fully investigated. We examine this in our
study in light of its growing importance.
Methods
Overview
We developed a Markov model [61] to compare
outcomes and costs of care in patients with chronic
schizophrenia or schizoaffective disorders that are
treated with risperidone versus olanzapine (“study
therapies”). The model focuses particular attention
on the likelihood of therapy switching and discon-
tinuation as a result of treatment-emergent side
effects, as the efﬁcacy of these two agents is similar
[62–69]. Patients are followed in the model up to
1 year, until they discontinue antipsychotic therapy,
or die, whichever comes ﬁrst.
Outcomes of interest include the incidence of
relapse of symptoms and side effects, including EPS,
selected prolactin-related disorders (amenorrhea,
breast disorders, and sexual dysfunction), and dia-
betes, expected change in body weight, and the per-
centage of patients remaining on initial therapy at
the end of 1 year. Expected costs of antipsychotic
therapy and psychiatric and nonpsychiatric services
were also examined. The perspective of the analysis
was that of a third-party payer.
Model parameters were estimated using pub-
lished and  unpublished  sources,  including  data
from clinical trials RIS-USA-112 and RIS-USA-79
[6,70,71], expert opinion, and by assumption. First-
order simulation (i.e., Monte Carlo) [72,73] tech-
niques were used to generate expected outcomes
and costs of care for a hypothetical cohort of
10,000 patients.
Description of  Markov Model
The model has six unique health states (four live
states plus two capture states). Live states were
deﬁned according to selected chronic side effects
(none, diabetes, prolactin-related disorders, both).
Capture states were deﬁned for patients who died or
discontinued study therapy.
Patients were assumed to receive risperidone
4.8 mg daily or olanzapine 12.4 mg daily; these
dosages were selected based on the mean modal
dosages observed during RIS-USA-112, a large, ran-
domized, multicenter, clinical trial of risperidone
and olanzapine in patients with chronic schizophre-
nia [6,70]. During each monthly cycle of the model,
patients were assumed to be at risk of side effects of
antipsychotic therapy and relapse of psychiatric
symptoms. Side effects that were incorporated into
the model included EPS, selected prolactin-related
disorders (i.e., amenorrhea, breast disorders, and
sexual dysfunction), and diabetes. The model also
simulates changes in body weight over time, which
is another potential side effect of therapy.
All side effects were assumed to be reversible
following therapy discontinuation [2,10,74–76].
Patients were assumed to be at risk of EPS and pro-
lactin-related disorders only during the ﬁrst 8 weeks
of therapy. Patients experiencing EPS or diabetes
and who discontinue antipsychotic therapy were
assumed to require short-term outpatient care and
treatment with oral medications. Patients experi-
encing prolactin-related disorders or diabetes who
remain on therapy were assumed to require long-
term follow-up and treatment. Diabetes was
assumed to take place independent of weight gain,
as this relationship for patients receiving antipsy-
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chotic therapy  has  not  been  well  established  in
the published literature [29,78]. All patients were
assumed to be free of diabetes at the time of model
entry. Complications of diabetes (e.g., diabetic
ketoacidosis, cardiovascular disease) were not
considered.
Patients were assumed to be at risk of weight
gain while on therapy; weight gain was assumed to
differ by therapy. Changes in body weight during
the ﬁrst 2 months of therapy were assumed to be
conditional on body mass index (BMI) at baseline,
consistent with published reports (including RIS-
USA-112) [29,34,79–81]. Weight gain was assumed
to be much less pronounced between 8 weeks and
1 year, consistent with published reports that this
phenomenon occurs principally in the ﬁrst 4 to
12 weeks of treatment [19,82–86] and that further
increases in body weight are not likely to exceed
30% [16,34].
All patients were assumed to be at risk of hos-
pitalization for relapse of symptoms. Only one
controlled study has examined the incidence of hos-
pitalization for symptom relapse over 1 year for ris-
peridone and haloperidol [71]. Given the lack of
data for olanzapine, rates of hospitalization for
relapse were assumed to be the same for patients
receiving risperidone and olanzapine.
Patients who experience side effects and/or
relapse of psychiatric symptoms were assumed
either to remain on therapy or discontinue and
switch to another agent. For patients experiencing
more than one such event (e.g., diabetes and EPS)
during any given cycle, the probability of therapy
discontinuation was assumed to be equal to that of
the event associated with the greater probability of
therapy discontinuation. As all patients who discon-
tinue antipsychotic therapy were assumed to switch
to another antipsychotic agent, they were assigned
the cost of outpatient services reﬂecting tapering of
initial antipsychotic therapy and the initiation of
another agent. No other additional costs of care
were considered for these patients.
EPS, Prolactin-Related Disorders, and Type 2 
Diabetes Mellitus
The risks of EPS and prolactin-related disorders
during the ﬁrst 2 months of risperidone and
olanzapine therapy were derived from analyses of
treatment-emergent adverse events of moderate or
greater severity and “probable” or “very likely”
relationship to study drug from the RIS-USA-112
study (Table 1) [6,70]. EPS was deﬁned to include
dyskinesia, dystonia, hyperkinesia, hypertonia,
tremor, and other unspeciﬁed extrapyramidal
events. Prolactin-related disorders included amen-
orrhea and unspeciﬁed menstrual disorders, breast
disorders (i.e., nonpuerperal lactation, breast pain),
and sexual dysfunction (i.e., anorgasmia, impo-
tence, sexual dysfunction, ejaculation failure,
decreased libido); the percentage of patients with
amenorrhea among those experiencing prolactin-
related disorders was 14%. Attention was focused
on symptomatic disease, and events categorized
only as “hyperprolactinemia” without further qual-
iﬁcation were not included, as they were assumed
not to require treatment and/or lead to discontinu-
ation of antipsychotic therapy. Rates of EPS over
8 weeks of therapy were 9.4% for risperidone and
7.8% for olanzapine; corresponding rates for prol-
actin-related disorders were 5% and 2%. Monthly
probabilities were derived as 1-e(–rate¥time) (Declining
exponential approximation of life expectancy
[DEALE]) (Tree Age Software Inc., Williamstown,
Massachusetts, 2001).
Rates of incident (i.e., new-onset) diabetes for
patients receiving risperidone and olanzapine were
estimated based on a review of data on “new” cases
of diabetes from published reports and research
abstracts [51–58]. While these studies are consid-
ered to have important limitations, the recent Con-
sensus Development Conference position [35] was
Table 1 Model probabilities
Parameter Value Source
EPS* (monthly for ﬁrst 2 months)
Risperidone 0.046 RIS-USA-112
Olanzapine 0.038 RIS-USA-112
Prolactin-related disorders* (monthly for ﬁrst 2 months)
Risperidone 0.024 RIS-USA-112
Olanzapine 0.010 RIS-USA-112
Diabetes (monthly)
Risperidone 0.0001 Pooled data†
Olanzapine 0.0002 Pooled data†
Hospitalization for relapse of  symptoms (monthly)
Risperidone 0.009 RIS-USA-79
Olanzapine 0.009 RIS-USA-79
Death from all causes (monthly) 0.0003 Brown et al. 1997
Therapy discontinuation following:
EPS 0.060 RIS-USA-112
Prolactin-related disorders 0.140 RIS-USA-112
Diabetes
Risperidone 0.450 Expert opinion‡
Olanzapine 0.450 Expert opinion‡
Hospitalization for relapse of  
symptoms
1.000 Assumption
Weight gain
>5 kg (11 lbs) since initiation 1.000 Russell et al. 2001§
£5 kg (11 lbs) since initiation 0.000 Russell et al. 2001§
*Treatment-emergent side effects (relation to drug probable or very likely).
†Pooled data [51–57].
‡Personal communication, Dr J Meyer and D Henderson.
§And references to Masand PS 1998, Sachs GS and Guille C 1988, CWGCTE
1999, and Pjil H and Meinders AE 1996.
Abbreviation. EPS, Extrapyramidal symptoms.
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that available data consistently showed an increased
risk of diabetes in patients treated with olanzapine
when compared with patients not receiving antip-
sychotic therapy, and that the risk in patients taking
risperidone was less clear at that time. Model esti-
mates of the monthly risk of diabetes were calcu-
lated by pooling data across studies using a
random-effects model in which individual estimates
from each study were weighted by the inverse of a
combination of within- and between-study varia-
tion, a technique commonly known as the DerSimo-
nian–Laird method [87]; monthly estimates
reﬂected an annual incidence of 1.5% and 2.3% for
risperidone- and olanzapine-treated patients,
respectively.
Body Weight and Weight Gain
The distributions of body weight and body mass
index (BMI) at therapy initiation were estimated
using data from RIS-USA-112 (Table 2). Estimates
of the change in body weight by BMI group (<25,
25–29, and ≥30 kg/m2) for the ﬁrst 2 months of
therapy also were based on data from RIS-USA-112
on the distribution of the change in body weight at
endpoint (or 8 weeks) (Table 3).
The mean monthly change in body weight from
months 2 through 12 for patients receiving risp-
eridone was calculated based on the mean weight
gain (1.5 kg) at endpoint among patients receiv-
ing risperidone in RIS-USA-112, and the mean
weight gain (2.49 kg) at 52 weeks among patients
receiving risperidone (4.9 mg daily) in the RIS-
USA-79 study [77]. The mean monthly change in
body weight for patients receiving olanzapine was
calculated based on the mean weight gain (3.3 kg)
at endpoint for patients receiving olanzapine in
the RIS-USA-112 study, and the mean weight gain
(5.2 kg) at 1 year as reported in two randomized,
double-blind, controlled trials [32,33]. A mean
weight gain at 1 year of 5.2 kg among patients
receiving olanzapine was estimated by interpola-
tion of the values for changes in body weight
(3.8 kg and 12.0 kg, respectively) at 1 year among
patients receiving olanzapine (11.6 mg daily and
16.3 mg daily), as changes in body weight for
patients receiving long-term therapy with olanzap-
ine 12.4 mg daily were not available from these
sources.
Table 2 Baseline body weight and body mass index (BMI)*
Parameter Value
Distribution of  body weight (kg)†
Min 41.7
25% 68.9
50% 81.6
75% 94.8
Max 167.4
Distribution of  body mass index (BMI) (kg/m2)‡
Min 10.0
25% 23.0
50% 27.0
75% 32.0
Max 57.0
*Source: RIS-USA-112; all randomized patients (n = 359).
†RIS-USA-112: Risperidone (84.2 ± 20.4) and olanzapine (82.9 ± 19.8)
(mean ± SD).
‡RIS-USA-112: Risperidone (29.4 ± 13.6) and olanzapine (28.0 ± 6.2)
(mean ± SD).
Table 3 Changes in body weight over 1 year following ther-
apy initiation, by study therapy and baseline BMI
Therapy/BMI Value
Distribution of  changes in body weight (kg) (monthly for ﬁrst 2 months 
of  therapy)*
Risperidone (4.8 mg daily)
BMI < 25
Min -1.80
25% 0.00
50% 0.68
75% 2.05
Max 4.75
BMI 25–29
Min -1.80
25% 0.00
50% 0.58
75% 1.83
Max 7.70
BMI ≥ 30
Min -4.50
25% -0.90
50% 0.45
75% 1.60
Max 7.70
Olanzapine (12.4 mg daily)
BMI < 25
Min -2.95
25% 0.80
50% 1.60
75% 2.70
Max 9.30
BMI 25–29
Min -3.85
25% -0.20
50% 1.025
75% 3.15
Max 9.75
BMI ≥ 30
Min -4.10
25% 0.00
50% 1.35
75% 2.30
Max 9.05
Mean change in body weight (kg) (monthly) (months 3–12)
Risperidone† (4.9 mg daily) 0.09
Olanzapine‡ (12.4 mg daily) 0.19
*RIS-USA-112: Risperidone (1.5 ± 3.5) and olanzapine (3.3 ± 5.1) (mean ± SD)
and by BMI as follows: Risperidone (1.8 ± 3.1) and olanzapine (4.1 ± 4.6)
(mean ± SD); Risperidone (1.9 ± 3.4) and olanzapine (3.0 ± 5.3) (mean ± SD);
Risperidone (1.0 ± 3.9) and olanzapine (2.6 ± 5.3) (mean ± SD).
†RIS-USA-79, based on 2.49 kg at 52 weeks.
‡Beasley et al. 1996 and 1997 and assumption, based on 5.2 kg at 52 weeks.
Abbreviation. BMI = Body mass index (kg/m2).
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Hospitalization for Relapse
The annual risk of hospitalization for relapse of
symptoms of schizophrenia among patients receiv-
ing risperidone (11.2%) was estimated based on the
1 year risk of hospitalization for relapse among
patients receiving risperidone in a randomized, dou-
ble-blind, placebo-controlled clinical trial [71,77].
Risk of hospitalization for relapse among olanza-
pine patients was assumed to be the same as that of
patients receiving risperidone.
Discontinuation of  Antipsychotic Therapy
Probabilities of therapy discontinuation for risperi-
done and olanzapine patients experiencing EPS and
prolactin-related disorders, respectively, were esti-
mated based on rates of study discontinuation in
RIS-USA-112 for treatment-emergent EPS and
prolactin-related disorders of moderate or greater
severity and “probable” or “very likely” relation-
ship to study drug. Six and 14% of patients who
experienced EPS and prolactin-related disorders,
respectively, discontinued antipsychotic therapy as a
result of these symptoms during RIS-USA-112. The
probability of discontinuation due to type 2 diabe-
tes was estimated to be 0.45 for patients receiving
either risperidone or olanzapine, based on expert
opinion (Drs J. Meyer and D. Henderson, June
2002). This probability reﬂects those patients who
are candidates for alternative antipsychotic thera-
pies who cannot maintain glucose control after
1 month of treatment.
As rates of therapy discontinuation following
body weight gain associated with antipsychotic
therapy are not available from clinical studies, this
probability was estimated based on published
recommendations [26,27,29,88,89] that patients
switch to a different antipsychotic agent if weight
gain is >5 kg (11 lbs) following therapy initiation,
or >2.3 kg (or 5 lbs) during any 4-week period of
treatment. A weight gain of 5 kg represents an
increase of more than 5% of initial body weight for
most patients and is associated with clinically mean-
ingful changes in morbidity and early mortality
[16]. This is also consistent with the recent recom-
mendation of the Consensus Development Confer-
ence [35] which suggested that a 5% or greater
increase in body weight be used as the threshold for
consideration of switching antipsychotic therapy.
Since 5% of 84 kg—the mean body weight at ran-
domization among patients in the Conley and Mah-
moud study [6]—represents an absolute increase in
body weight of 4.2 kg, the threshold of an excess of
5 kg is—if anything—a conservative model assump-
tion. In our base-case analyses, only those patients
with weight gain of >5 kg [11 lbs]) were considered.
The probability of therapy discontinuation follow-
ing weight gain for this scenario was assumed to be
equal to one.
All patients experiencing hospitalization for
relapse of symptoms of schizophrenia were assumed
to discontinue therapy.
Mortality
The annual rate of all-cause mortality among
patients with chronic schizophrenia (0.036%)
receiving risperidone or olanzapine was estimated
by multiplying the annual mortality rate among per-
sons aged 40 to 44 years (the mean age of patients
participating in RIS-USA-122 was 40 years) in the
general population (236 per 100,000) [90], by the
standardized mortality ratio (SMR) reported in a
recent meta-analysis of studies of mortality in
patients with schizophrenia (i.e., 1.51) [91].
Resource Utilization
Estimates of the utilization of psychiatric and
nonpsychiatric services were developed using pub-
lished sources and expert opinion (Table 4). Patients
who experience EPS were assumed to require dose
adjustment and additional treatment with anti-
cholinergic drugs (benztropine mesylate 2 mg daily)
[2,92] for the ﬁrst 60 days; no additional outpatient
visits were assumed to be incurred for the manage-
ment of EPS. While baseline testing of serum prol-
actin levels is not recommended in the risperidone
package insert, we conservatively assumed that
patients receiving risperidone would receive base-
line serum prolactin tests prior to treatment initia-
tion, based on expert opinion (Dr K Miller, July
2002) and the published literature [93]. Those expe-
riencing symptomatic prolactin-related disorders,
risperidone or olanzapine, were assumed to require
additional diagnostic services, including two endo-
crinologist visits, repeat serum prolactin levels, a
plasma gonadotropin test (FSH/LH) (females only
58% [70]), a pregnancy test (also, females only), a
thyroid stimulating hormone (TSH) test, and a urea/
creatinine determination; one-fourth of these
patients were assumed to undergo magnetic reso-
nance imaging (MRI) [93,94] of the brain to rule
out the presence of a pituitary adenoma. Patients
experiencing amenorrhea who remain on therapy
were assumed to receive a bone mineral density
(BMD) test and oral contraceptive therapy. They
also were assumed to require two additional follow-
up visits with an endocrinologist, two serum prol-
actin tests, one BMD evaluation, and to remain on
oral contraceptive therapy.
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All treated patients were assumed to undergo
fasting blood glucose (FBG) tests to screen for ther-
apy-induced hyperglycemia [95]; patients receiving
risperidone and olanzapine were assumed to
undergo FBG testing biannually, based on expert
opinion (Drs J Meyer and D Henderson, June 2002)
and consistent with recommendations of the recent
Consensus Development Conference [35]. Patients
who develop type 2 diabetes mellitus were assumed
to require additional diagnostic services, including
one additional psychiatrist visit, referral to an endo-
crinologist, and  two  FBG  tests.  Fifty-ﬁve  percent
of patients also were assumed to undergo an oral
glucose tolerance test (OGTT); all patients were
assumed to undergo hemoglobin A1c testing at the
time of diagnosis. All patients diagnosed with type 2
Table 4 Estimated utilization of  medical-care services
Parameter Value Source
Psychiatric services (monthly)
Residential treatment (no. admissions) 0.02 Carter et al. 1998
Emergency crisis/intervention (no. visits) 0.03 Carter et al. 1998
Day treatment (no. visits) 1.14 Carter et al. 1998
Outpatient treatment (no. visits) 2.11 Carter et al. 1998
Case management (no. visits) 1.83 Carter et al. 1998
Outpatient care for cross-tapering medications following discontinuation of  initial 
antipsychotic therapy
Specialist (no. visits) 2 Peuskens, 2000
Nonpsychiatric services
Outpatient care for EPS
Days of  oral treatment with benztropine mesylate (2 mg/d) 60 Gerlach 1999, Gray 2000
Outpatient care for prolactin-related disorders
At initiation of  therapy (risperidone only)
Serum prolactin levels (no. tests) 1 Davies et al. 1997/Expert opinion*
Diagnosis
Specialist (endocrinologist) (no. visits) 2 Expert opinion*
MRI of  the brain (no. tests) 0.25 Expert opinion*
Plasma gonadotropin levels (no. tests) (females only) 1 Expert opinion*
Pregnancy test (no. tests) 1 Davies et al. 1997
Serum prolactin levels (no. tests) 1 Expert opinion*
Thyroid stimulating hormone (TSH) (no. tests) 1 Expert opinion*
Urea/creatinine 1 Expert opinion*
Bone mineral density (if  amenorrhea)§ 1 Expert opinion*
Monthly thereafter
Specialist (endocrinologist) (no. visits) 0.18‡ Expert opinion*
Serum prolactin levels (no. tests) 0.18‡ Expert opinion*
Bone mineral density (if  amenorrhea)§ (%) 0.09‡ Expert opinion*
Oral contraceptive therapy (if  amenorrhea)§ (%) 100 Expert opinion*
Outpatient care for diabetes
Screening
Fasting blood glucose (no. tests) (monthly)
Risperidone 0.17† Luna B, 2001
Olanzapine 0.17† Expert opinion†
Diagnosis Expert opinion†
Specialist (psychiatrist) (no. visits) 1 Expert opinion†
Specialist (endocrinologist) (no. visits) 1 Expert opinion†
Fasting blood glucose (no. tests) 2 Expert opinion†
Hemoglobin A1c (no. tests) 1 Expert opinion†
Oral glucose tolerance test 0.55 Expert opinion†
Purchase of  blood glucose monitoring system (per patient) 1 Expert opinion†
Monthly thereafter
Specialist (endocrinologist) (no. visits) 1 Expert opinion†
Primary care practitionner 1 Expert opinion†
Fasting blood glucose (no. tests) 2¶ Expert opinion†
Hemoglobin A1c (no. tests) 1 Expert opinion†
Insulin therapy (% patients) 45 Expert opinion†
Oral treatment (% patients) 55 Expert opinion†
Counseling for weight reduction and maintenance
Percentage of  patients (among those who discontinue therapy due to weight gain) 50 Assumption
Number of  individual sessions** 7 Umbricht et al. 2001
*Dr K Miller, July 2002.
†Drs J Meyer and D Henderson.
‡Based on two visits, two prolactin levels and one BMD evaluation.
§Or two annually.
¶Or one every 2 weeks.
**Therapist and registered dietician during each session.
Abbreviations. EPS, Extrapyramidal symptoms; MRI, magnetic resonance imaging.
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diabetes were assumed to receive treatment for this
condition for 1 month following diagnosis prior to
consideration of discontinuation of therapy. Diabe-
tes was assumed to require chronic therapy and
follow-up care for patients remaining on antipsy-
chotic therapy. Clinical management of diabetes
was assumed to involve bimonthly FBG tests,
monthly evaluation of hemoglobin A1c levels, die-
tary restriction, and treatment with insulin (45% of
patients) or oral hypoglycemic drugs (55%); all
patients were assumed to purchase a personal blood
glucose monitoring system. Patients requiring insu-
lin were assumed to receive twice daily injections
(i.e., 25 units of NPH plus 10 units of regular insu-
lin before breakfast and 10 units of NPH plus 5
units of regular insulin before dinner); those receiv-
ing oral therapy were assumed to be treated with
metformin 500 mg twice daily. All patients requir-
ing insulin therapy were assumed to be referred to
an endocrinologist for initiation of therapy and
monthly follow-on care. No additional follow-up
care other than routine psychiatric visits was
assumed to be required for patients whose diabetes
was treated by psychiatrists.
Fifty percent of patients experiencing an increase
in body weight >5 kg (or 11 lbs) were assumed to
participate in a weight-management program. A
variety of behavioral interventions have been rec-
ommended in the published literature for patients
who gain considerable amounts of weight during
treatment with antipsychotics [23,24,26,96,97],
and in particular, among those with maximal
weight gains between 2.5 and 8.0 kg [28,96]. This
program was assumed to include elements of cog-
nitive behavior therapy and counseling, and to con-
sist of seven individual sessions with a therapist and
a registered dietician, respectively, as reported in a
study of treatment of weight gain among patients
receiving atypical antipsychotics [96].
Patients  discontinuing  antipsychotic  therapy
due to hospitalization for relapse of symptoms or
side effects of therapy were assumed to require
additional outpatient services for switching antipsy-
chotic agents (i.e., cross-tapering). Cross-tapering
was also recommended by the Consensus Develop-
ment Conference for patients who switch antipsy-
chotic therapy following increases of body weight
of 5% or more or for any other reason [35]. Cross-
tapering was assumed to involve two additional
psychiatrist visits over a period of 4 weeks; these are
required for tapering down the daily dose of the
previous neuroleptic agent, allowing for a wash-out
period, and up-titrating the new treatment until a
therapeutic response is achieved [98].
All patients hospitalized for relapse of symptoms
were assumed to receive inpatient treatment. One-
year estimates of the proportions of treated patients
undergoing residential treatment, day treatment,
case management, outpatient visits, and emergency/
intervention services for the treatment of psychiatric
symptoms were based on a retrospective study of
the use of mental health services among 63 schizo-
phrenic patients treated with risperidone [99]. The
utilization  of  psychiatric  services  was  assumed  to
be the same for patients receiving risperidone or
olanzapine.
Costs of  Care
Estimated costs of psychiatric and nonpsychiatric
services are reported in Table 5. All costs were
adjusted to 2003 (August) average price levels using
the Consumer Price Index for Medical Care Services
[100]. Costs of medications were estimated using
average wholesale prices [101]. Average daily doses
of risperidone (4.8 mg) and olanzapine (12.4 mg)
were estimated based on mean daily modal doses in
RIS-USA-112; assumed average doses of all other
medications were based on the recommended daily
dose [101,102] and expert opinion. The cost of a
blood glucose monitoring system was estimated
based on a survey of three on-line and three local
pharmacies in the Boston area. An estimated dis-
pensing fee was added to the cost of each prescrip-
tion [103]. The cost of inpatient care for relapse as
well as the costs of all other psychiatric services was
based on a published retrospective study of mental
health use among schizophrenic patients [99]. The
costs of all specialist visits and diagnostic tests and
procedures were estimated based on payment rates
established under Medicare’s Resource-Based Rela-
tive Value Scale (RBRVS) [104]. The cost of a nutri-
tional counseling session by a registered dietician
was estimated based on the average hourly fee for
an outpatient consultation reported in an analysis
of commercial weight-loss programs in the Boston
area [105].
Analyses
First-order simulation (i.e., Monte Carlo) [72,73]
techniques were used to generate expected out-
comes and costs for a hypothetical sample of
10,000 patients assumed to initiate treatment with
risperidone or olanzapine. First-order simulation
allows for random sampling from distributions rep-
resenting individual and/or temporal variation in
patient characteristics and/or outcomes.
During simulation, 10,000 individuals alterna-
tively assumed to receive risperidone or olanzapine
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were randomly stepped through the Markov proc-
ess—one person at a time—yielding individual
expected values for all measures of interest. Clinical
and economic outcomes were subsequently summa-
rized for each treatment group using Data Interac-
tive ActiveX DLL (Tree Age Software Inc.,
Williamstown, Massachusetts, 2001) and Microsoft
Excel 2000 (Microsoft Corporation, 2000) as the
host application. Because the expected duration of
therapy could differ between the two treatment
groups, expected monthly costs of care were calcu-
lated by dividing total costs of care up to 12 months
by the estimated mean number of months on ther-
apy for patients in each treatment group.
One- and two-way sensitivity analyses were con-
ducted to examine the robustness of study ﬁndings
with respect to changes in selected parameter esti-
mates. A set of two-way sensitivity analyses was
undertaken in which estimated changes in body
weight gain were allowed to vary simultaneously
across a range of probabilities (0–1) of therapy dis-
continuation for this reason.
Results
Estimated outcomes and costs of care per month of
therapy are presented in Table 6. The expected per-
centage of patients experiencing EPS was 9.2%
and 7.2% for risperidone and olanzapine, respec-
tively. Corresponding ﬁgures for prolactin-related
disorders were 5.4% and 2.2%, consistent with
ﬁndings from the RIS-USA-112 study. Approxi-
mately 1.7% of olanzapine patients were estimated
to experience new-onset type 2 diabetes mellitus,
compared with 1% among those receiving risperi-
done. Mean weight gain was estimated to be
1.7 kg and 3.9 kg for risperidone and olanzapine,
respectively, at the end of 1 year. Approximately
Table 5 Estimated unit costs of  care
Parameter Value Source
Medications ($)
Acquisition costs
Risperidone (4.8 mg, daily) $12.1 Red Book, 2003
Olanzapine (12.4 mg, daily) $15.8 Red Book, 2003
Oral therapy for EPS (2 mg benztropine mesylate daily) $0.2 Red Book, 2003
Insulin (25/10 U AM and 10/5 U PM)* $2.1 Red Book, 2003
Metformin (1000 mg daily) $1.6 Red Book, 2003
Oral contraceptives (monthly) $32.8 Red Book, 2003
Blood glucose monitoring system (patient) $60.3 Pharmacy Survey†
Dispensing fee (per 90-day prescription) (monthly) $2 PBM, 1997
Psychiatric services ($)
Inpatient care (per admission)
Relapse of  symptoms $12,695 Carter et al. 1998
Other psychiatric care
Residential treatment (per admission) $4549 Carter et al. 1998
Emergency crisis/intervention $441 Carter et al. 1998
Day treatment‡ $256 Carter et al. 1998
Outpatient treatment§ $588 Carter et al. 1998
Case management $14 Carter et al. 1998
Nonpsychiatric services ($)
Outpatient care
Specialist visit (psychiatrist or endocrinologist) $141 RBRVS (99205), 2003
Primary care practitioner (PCP) visit $59 RBRVS (99214), 2003
Bone mineral density test $46 RBRVS (78350), 2003
Fasting blood glucose $6 RBRVS (82947), 2003
Hemoglobin A1c $15 RBRVS (83036), 2003
MRI of  brain $682 RBRVS (70552), 2003
Oral glucose tolerance test (OGTT) $20 RBRVS (82951), 2003
Plasma gonadotropin levels $57 RBRVS (83001, 83002), 2003
Pregnancy test $9 RBRVS (81025), 2003
Serum prolactin levels $29 RBRVS (84146), 2003
Thyroid stimulating hormone (TSH) $26 RBRVS (84443), 2003
Urea/creatinine $14 RBRVS (84520, 82565), 2003
Counseling for weight reduction and maintenance
Therapist session $96 RBRVS (99403), 2003
Registered dietician individual session $87 Spielman et al. 1992
*Includes cost of  syringes for twice a day administration.
†Based on a survey of  three on-line and three local pharmacies in the Boston area.
‡Assumed weighted average of  <6 h and >6 h duration.
§Includes assessment, counseling, medication management, and collateral services.
Abbreviations. EPS, Extrapyramidal symptoms; MRI, Magnetic resonance imaging.
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4% and 25% of risperidone- and olanzapine-
treated patients were estimated to experience an
increase in body weight ≥7%. The percentage of
patients remaining on therapy at the end of 1 year
was estimated to be 76.9% for risperidone and
45.6% for olanzapine; the difference reﬂects a
higher incidence of side effects leading to therapy
discontinuation among patients receiving olanzap-
ine. Consistent with these ﬁndings, the mean
expected number of months on study therapy was
10.6 for risperidone and 8.0 for olanzapine. Forty-
two percent of olanzapine patients were projected
to discontinue antipsychotic therapy due to
increases in body weight exceeding 5 kg; the corre-
sponding percentage for risperidone was 5%.
Expected rates of hospitalization for relapse of psy-
chiatric symptoms and mortality per month of
therapy were the same in the two treatment groups
(0.9% for relapse, and 0.03% for mortality), con-
sistent with our assumptions.
Expected mean total costs of care per month of
therapy were $2163 for risperidone and $2316 for
olanzapine,  or  a  difference  of  $153.  Costs  of
antipsychotic therapy,  diagnosis  and  treatment  of
side  effects,  and  discontinuation  and  switching
of antipsychotic therapy were higher among olanza-
pine patients.
Sensitivity Analyses
Results from one-way sensitivity analyses (Table 7)
suggest that study ﬁndings were overall insensitive
to changes in any single model parameter, with the
exception of the change in body weight and the
assumed probability of therapy discontinuation fol-
lowing weight change in excess of 5 kg (or 11 lbs).
Our ﬁndings suggest that the value of this probabil-
ity would have to be lower than 0.1 for the propor-
tion of patients remaining on therapy at the end of
1 year to be the same for risperidone and olan-
zapine. Costs of care per month of therapy were
consistently lower for risperidone. Results from
two-way sensitivity analyses are reported in
Table 8.
Discussion
The purpose of our study was to examine the
potential impact of side effects on therapy discon-
tinuation and switching and the cost of psychiatric
and nonpsychiatric services in patients with chronic
schizophrenia or schizoaffective disorders receiving
risperidone or olanzapine. Our ﬁndings indicate
that patients treated with risperidone would be
more likely to remain on initial therapy at the end
of 1 year (76.9% vs. 45.6%, respectively, for
Table 6 Estimated outcomes at 1 year following therapy initiation and cost of  care per month of  therapy
Treatment
Risperidone Olanzapine Difference
Clinical outcomes
Patients on initial therapy (%) 76.9 45.6 31.3
Mean time on therapy (months) 10.6 8.0 2.6
Side effects
EPS (%) 9.2 7.2 2.0
Prolactin-related disorders (%) 5.4 2.2 3.2
Type II diabetes (%) 1.0 1.7 -0.7
Body weight (kg) (mean)
Baseline 83.4 83.7 -0.3
End of  1 year or therapy discontinuation 85.2 87.6 -2.4
Change from baseline 1.7 3.9 -2.2
Patients with body weight gain ≥7% than baseline (%) 3.7 25.4 -21.7
Discontinuation of  antipsychotic therapy and switching (%)
Weight gain 5.3 42.3 -37.0
Other 17.8 12.1 5.7
Total 23.1 54.4 -31.3
Cost of care (mean)
Antipsychotic therapy $369 $479 –$110
Screening $4 $1 $3
Side effects
EPS* $0.11 $0.11 $0
Prolactin-related disorders $5 $2 $2
Diabetes $1 $2 –$1
Weight gain $3 $33 –$31
Total $8 $37 –$29
Discontinuation and switching therapies $6 $19 –$13
Psychiatric services $1776 $1779 –$3
Total $2163 $2316 –$153
*Cost of  EPS treatment were higher for risperidone ($1.5 vs. $0.9 at 1 year) but the same per month of  therapy.
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Table 7 One-way sensitivity analyses of  impact of  selected model parameters on patient outcomes and cost of  care per month
of  therapy up to 1 year
Parameter
Risperidone Olanzapine Difference
(%)
On Tx
Months
On Tx
D
Weight* Cost
(%)
On Tx
Months
On Tx
D
Weight* Cost
(%)
On Tx
Months
On Tx
D
Weight†
D 
Cost†
Base case 76.9 10.6 1.7 $2163 45.6 8.0 3.9 $2316 31.3 2.6 -2.2 –$153
Probability of  EPS
2 ¥ base case (RIS) 72.4 10.3 1.7 $2169 45.7 8.0 3.9 $2316 26.8 2.2 -2.2 –$147
OLZ = RIS 76.9 10.6 1.7 $2163 44.1 8.0 4.0 $2322 32.9 2.6 -2.3 –$159
Probability of  PRD
2 ¥ base case (RIS) 73.6 10.3 1.7 $2168 45.7 8.0 3.9 $2316 27.9 2.3 -2.3 –$148
Probability of  DM
2 ¥ base case (OLZ) 76.9 10.6 1.7 $2163 44.4 8.0 4.0 $2323 32.5 2.6 -2.3 –$159
RIS = OLZ 76.1 10.5 1.7 $2165 45.7 8.0 3.9 $2316 30.5 2.5 -2.2 –$152
Probability of  discontinuation following EPS
0.5 ¥ base case 77.7 10.6 1.7 $2170 45.7 8.0 4.0 $2321 32.0 2.6 -2.2 –$151
2 ¥ base case 75.1 10.4 1.7 $2166 43.9 7.8 3.9 $2316 31.1 2.5 -2.2 –$150
Probability of  discontinuation following PRD
0.5 ¥ base case 77.7 10.6 1.7 $2166 45.7 8.1 3.9 $2312 32.1 2.6 -2.2 –$146
2 ¥ base case 75.0 10.3 1.7 $2172 44.1 7.9 4.0 $2318 30.9 2.4 -2.2 –$147
Probability of  discontinuation following diabetes
0.5 ¥ base case 77.2 10.6 1.7 $2162 45.5 8.0 3.9 $2322 31.7 2.6 -2.2 –$160
2 ¥ base case 76.5 10.5 1.7 $2169 45.5 8.0 3.9 $2314 31.0 2.6 -2.2 –$145
Change in body weight (OLZ)
0.5 ¥ base case 76.9 10.6 1.7 $2163 74.6 10.4 2.3 $2286 2.3 0.2 -0.6 –$122
2 ¥ base case 76.9 10.6 1.7 $2163 30.4 5.4 5.3 $2365 46.5 5.1 -3.6 –$202
Change in body weight (RIS)
2 ¥ base case 46.6 7.5 3.4 $2081 45.7 8.0 3.9 $2316 0.9 -0.4 -0.5 –$235
Probability of  discontinuation following cumulative weight gain >5 kg (11 lbs)
0 80.7 10.8 1.7 $2161 82.3 11.0 4.6 $2293 -1.7 -0.1 -2.9 –$131
0.1 78.2 10.7 1.7 $2168 62.3 9.9 4.4 $2305 15.9 0.9 -2.6 –$138
0.3 77.6 10.6 1.7 $2161 50.2 8.2 4.2 $2315 27.4 2.4 -2.5 –$154
0.5 76.5 10.5 1.7 $2166 47.1 8.4 4.1 $2310 29.4 2.1 -2.4 –$144
0.7 77.5 10.6 1.7 $2163 46.2 8.2 4.1 $2308 31.3 2.4 -2.4 –$145
Probability of  discontinuation following weight gain >2.3 kg (5 lbs) in 4-week period
0.5 70.7 9.8 1.6 $2167 41.0 7.1 3.8 $2322 29.6 2.7 -2.2 –$155
1 65.3 9.1 1.5 $2168 36.7 6.1 3.5 $2317 28.6 3.0 -2.0 –$149
Cost of  diagnoses and treatment of  PRD
2 ¥ base case — — — $2168 — — — $2318 — — — –$151
Cost of  weight management programs
0 — — — $2161 — — — $2283 — — — –$122
0.5 ¥ base case — — — $2162 — — — $2299 — — — –$137
Cost of  discontinuation/switching
0 — — — $2157 — — — $2297 — — — –$140
0.5 ¥ base case — — — $2160 — — — $2306 — — — –$146
2 ¥ base case — — — $2170 — — — $2335 — — — –$166
*Versus baseline (kg).
†Risperidone minus olanzapine.
Other than (%) On Tx, all other parameters reported as means.
Abbreviations. EPS, extrapyramidal symptoms; OLZ, olanzapine; PRD, prolactin-related disorders; RIS, risperidone.
olanzapine); costs of care per month of therapy
were estimated to be $153 (or 7%) lower among
risperidone-treated patients. Our ﬁndings are
driven primarily by higher weight gain resulting in
therapy discontinuation and switching, and by
higher costs of medication and side effects of treat-
ment among patients receiving olanzapine. The
estimated proportion of olanzapine-treated patients
who would experience an increase in body weight
≥7% was approximately 25% (vs. 4% for risperi-
done). To the best of our knowledge, our study is
the ﬁrst to address these issues for patients receiv-
ing atypical agents.
As EPS is typically controlled with reductions in
drug dosage and treatment with relatively inexpen-
sive anticholinergic medications, its overall clinical
and economic impact is minimal, as supported by
our ﬁndings. However, the expected incidence of
other side-effects—namely, prolactin-related disor-
ders, weight gain, and diabetes—inﬂuence out-
comes in this patient population. Symptomatic
prolactin-related disorders, while infrequent, occur
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more often among patients receiving risperidone.
The decision to discontinue antipsychotic therapy
among these patients, however, is heavily weighted
in favor of the degree of control of psychiatric
symptoms. Most patients who experience drug-
induced prolactin-related disorders are likely to
remain on therapy provided that they undergo
periodic outpatient follow-up and treatment as
appropriate. While the costs of medical services
associated with screening, diagnosis, follow-up, and
treatment of patients with hyperprolactinemia are
not negligible, they represented only about 1.4% of
expected monthly costs in our analysis, reﬂecting
the relatively low incidence of symptomatic disease.
Rates of EPS and prolactin-related disorders were
considered for the ﬁrst 8 weeks of treatment only,
based on evidence that these side effects typically
occur early in the course of therapy, and lessen and/
or stabilize subsequently [75,76]. We believe that
the inclusion of long-term risks for these side effects
would have had minimal impact in our ﬁndings,
given the small magnitude of costs associated with
their treatment and the low rates of discontinuation
of antipsychotic therapy for these reasons.
While all atypical agents cause some degree of
weight gain, this is more frequent and marked for
olanzapine. Findings from controlled clinical trials
of olanzapine suggest that mean weight gain among
patients receiving dosages similar to that assumed in
our analysis ranges from 3.5 to 8 kg over 1 year
[18,32,33], although higher values have been
reported [17]. In light of these ﬁndings, we believe
that our estimate of an approximately 4 kg increase
in body weight at 1 year among olanzapine-treated
patients (12.4 mg/day) is conservative. Strengths of
our analysis include the fact that we modeled early
changes in body weight conditional on a patient’s
initial BMI, and the assumption of gradual plateau-
ing of weight over time, both consistent with the
current characterization of drug-related weight gain
in the published literature. Our estimates for the
early months of treatment, where increases in body
weight have been demonstrated to be highest [16],
are based on the actual distribution of individual
changes in weight among 316 patients who partic-
ipated in a randomized head-to-head comparison of
the study therapies.
We are aware that our model generates estimates
of the proportions of patients who would discon-
tinue olanzapine and risperidone therapy over
1 year that may be inconsistent with current clinical
practice. In two randomized controlled trials, the
percentage of risperidone and olanzapine patients
remaining on therapy has been reported to be 72%
and 77.2%, respectively, at 8 weeks in one study
(NS), and 47.3% and 56% at 28 weeks in the other
(NS) [6,63]. In two other prospective clinical trials,
rates of discontinuation for any reason were
reported not to differ [106,107]. A meta-analysis of
studies of second-generation antipsychotics in
patients with treatment-resistant schizophrenia esti-
mated that completion rates for risperidone and
olanzapine were 84.8% and 65.7%, respectively,
over a similar period of follow-up [108]. Unfortu-
nately, published data were not available to use for
the probability of therapy discontinuation condi-
tional on changes in body weight. Thus, we based
our estimates on published recommendations con-
cerning therapy change following weight gain and
the threshold for “signiﬁcant” body weight gain
(7%) employed by the US Food and Drug Admin-
istration. To examine the robustness of our ﬁndings,
we conducted extensive sensitivity analyses in
which we varied the probability of therapy discon-
tinuation due to changes in body weight in excess of
5 kg from zero to one. The value of this probability
Table 8 Two-way sensitivity analyses of  impact of  changes in body weight and assumed probability of  therapy discontinuation
following weight gain on patient outcomes and cost of  care per month of  therapy up to 1 year
Parameter
Risperidone Olanzapine Difference
(%)
On Tx
Months
On Tx
D
Weight* Cost
(%)
On Tx
Months
On Tx
D
Weight* Cost
(%)
On Tx
Months
On Tx
D
Weight†
D 
Cost†
Base case 76.9 10.6 1.7 $2163 45.6 8.0 3.9 $2316 31.3 2.6 -2.2 –$153
Olanzapine weight gain (0.5 ¥ base case)
Probability of  discontinuation following weight gain >5 kg (11 lbs)
0 80.7 10.8 1.7 $2161 82.3 11.0 2.3 $2272 -1.7 -0.1 -0.6 –$111
0.1 78.2 10.7 1.7 $2168 79.1 10.8 2.3 $2272 -0.9 -0.1 -0.6 –$104
0.3 77.6 10.6 1.7 $2161 77.2 10.6 2.2 $2273 0.4 0.0 -0.5 –$112
0.5 77.0 10.5 1.7 $2166 76.0 10.5 2.3 $2279 1.0 0.0 -0.5 –$113
0.7 77.4 10.6 1.7 $2163 75.6 10.5 2.3 $2281 1.8 0.1 -0.6 –$118
1 76.9 10.6 1.7 $2163 74.6 10.4 2.3 $2286 2.3 0.2 -0.6 –$122
*Versus baseline (kg).
†Risperidone minus olanzapine.
Other than (%) On Tx, all other parameters reported as means.
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would have to be less than 0.1 for the proportion of
patients remaining on therapy at the end of 1 year
to be the same for risperidone and olanzapine.
Increasing awareness of the link between adiposity
and adverse clinical and economic outcomes has led
to development of recommendations for close mon-
itoring and more aggressive management of weight
gain in this patient population. Strictly speaking,
our model therefore provides estimates of outcomes
that would result from implementation of these
guidelines.
Finally, the increased number of cases of hyper-
glycemia and diabetes mellitus in patients receiving
olanzapine is of concern. Although the true inci-
dence of these conditions is unknown, observa-
tional studies suggest that the risk of diabetes
mellitus among patients receiving olanzapine is
higher than that reported in early trials of the drug
[94,109,110]. The position of the Consensus Devel-
opment Conference [35] is also supportive of this
ﬁnding. While our estimates are not adjusted for
body weight and BMI, weight gain has been
reported to be a characteristic of patients who
develop insulin-dependent diabetes [78]. In this 5-
year naturalistic study of clozapine—the longest
follow-up study addressing this issue conducted to
date—neither weight, change in weight, BMI, nor
change in BMI were shown to be associated with
the development of conﬁrmed or unconﬁrmed
diabetes mellitus.
We note that our assumed dosages of study ther-
apies (12.5 mg (olanzapine) and 4.8 mg (risperi-
done) per (day) are consistent with prescription
data from the IMS National Disease and Therapeu-
tic Index (NDTI) for years 2001 and 2002 [111],
which reports a range from 12.8 to 13.7 mg daily
for olanzapine, and from 3.99 mg to 4.08 mg for
risperidone. We assumed that the effectiveness of
risperidone and olanzapine in controlling psychiat-
ric symptoms would not differ and that they would
result in similar utilization of psychiatric services.
Although perhaps debatable, both agents have been
shown to be similarly efﬁcacious in reducing posi-
tive and negative symptoms of psychosis. Two
head-to-head randomized controlled trials of these
agents have been conducted to date [6,63]. The
study by Tran et al. reported superior efﬁcacy of
olanzapine in the control of negative symptoms,
but its design has been criticized due to the rapid
titration and high dosages of risperidone [112–
115]; experience with risperidone suggests that
higher drug dosages may be associated with lower
efﬁcacy and higher rates of side effects. The other
randomized, double-blind head-to-head compari-
son of these agents was the RIS-USA-112 study, the
ﬁndings of which were reported by Conley and
Mahmoud [6]. Greater reductions in the severity of
positive and affective symptoms were observed
among patients receiving risperidone, and there
was no efﬁcacy measure on which olanzapine was
found to be superior. A prospective, nonrand-
omized comparison [106] of these agents (mean
modal dosages: olanzapine, 17.7 mg daily; risperi-
done, 7.9 mg daily) reported that olanzapine-
treated patients were more likely to “maintain
response” than risperidone-treated patients; the dif-
ference in the percentage of patients who improved
based on Positive and Negative Syndrome Scale
(PANSS) at study endpoint was not statistically sig-
niﬁcant, however. Moreover, there is no compara-
tive data suggesting that rates of hospitalization for
relapse of psychiatric symptoms—a key cost driver
in this patient population—differ between patients
receiving risperidone or olanzapine. The above-
cited prospective, nonrandomized study of these
agents—which included economic outcomes—did
not report rates of hospitalization for relapse for
psychiatric symptoms. Finally, a small, retrospec-
tive, naturalistic study [66] of olanzapine (mean
daily dose: 15.2 mg) and risperidone (4.2 mg daily)
reported signiﬁcantly higher readmission rates at
1 year for patients receiving olanzapine. After care-
ful consideration of the clinical relevance of the
dosages employed in our model, and the contro-
versy sparked by evidence from published sources,
we believe that our assumption of similar efﬁcacy is
reasonable, and warrants an examination of the
outcomes and cost of care associated with these
agents in light of their side effects.
Despite these limitations, we believe our study
has important clinical and economic implications.
While patients receiving risperidone are more likely
to experience increased risks of EPS and sympto-
matic prolactin-related disorders, those treated with
olanzapine are more likely to experience greater
gains in body weight, a slightly higher risk of dia-
betes mellitus, higher rates of therapy discontinua-
tion, and higher costs of care per month of therapy
over 1 year. Our ﬁndings accordingly may be of
interest to clinicians and others interested in out-
comes and costs of mental health services among
patients with chronic schizophrenia or schizoaffec-
tive disorders.
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